Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Q2 Revenues Down, Amid Cash Payments

NEW YORK, July 29 - CombiMatrix recorded $6,000 in revenues for the second quarter of 2003, down from $438,000 for the year-ago period, the company's parent Acacia Research, reported today.

 

These paltry revenues came atop $5.8 million in cash payments from CombiMatrix' partners, including $4.5 million in milestone payments from Roche to commercialize its microarray system, $308,000 to deliver prototype products to Roche, and $1 million to Toppan Printing of Japan in a deal announced in May to develop electrochemical-detection microarrays. These payments are being recorded as deferred revenues, Acacia said.

 

For the quarter, CombiMatrix' R&D expenses of $2.2 million, compared to $5 million for the year-ago period.

 

The division's net losses came to $5.2 million, compared to $5.9 million for the second quarter of 2002.

 

At the end of June, CombiMatrix, of Squolamie, Wash., had $19.3 million in cash, cash equivalents, and short-term investments.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.